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ABSTRACT: Glycogen synthase kinase 3β (GSK-3β) is a serine-threonine kinase belonging to the CMGC
family that plays a key role in many biological processes, such as glucose metabolism, cell cycle regulation,
and proliferation. Like most protein kinases, GSK-3β is regulated via multiple pathways and sites. We
performed all-atom molecular dynamics simulations on the unphosphorylated and phosphorylated unbound
GSK-3β and the phosphorylated GSK-3β bound to a peptide substrate, its product, and a derived inhibitor.
We found that GSK-3β autophosphorylation at residue Tyr
216 results in widening of the catalytic groove,
thereby facilitating substrate access. In addition, we studied the interactions of the phosphorylated GSK-3β
with a substrate and peptide inhibitor located at the active site and observed higher affinity of the inhibitor to
the kinase. Furthermore, we detected a potential remote binding site which was previously identified in other
kinases. In agreement with experiments we observed that binding of specific peptides at this remote site leads
to stabilization of the activation loop located in the active site. We speculate that this stabilization could
enhance the catalytic activity of the kinase. We point to this remote site as being structurally conserved and
suggest that the allosteric phenomenon observed here may occur in the protein kinase superfamily.
Glycogen synthase kinase 3(GSK-3)
1 is aubiquitousserine/
threonine kinase that is involved in many biological pathways
including glucose metabolism, cell apoptosis, neurological dis-
orders, and heat shock response regulation (1, 2). In contrast to
most protein kinases,GSK-3 becomes fully activated upon cellu-
larrestandinhibitedatcellulararousal.Thekinaseisinhibitedby
externalphosphorylationofSer
21intheRisoformandofSer
9inβ.
Several protein kinases are responsible for this phosphoryla-
tion, among them PKA, PKB, and PKC (3, 4). Intriguingly,
GSK-3 phosphorylates itself at Tyr
216, a residue located at the
catalyticsite(5).Thisautophosphorylationeventcausesactivation
rather than inhibition. Since GSK-3 has multifaceted roles in
many signaling pathways, an elevation or relegation of its normal
activity level is associated with several diseases, including type II
diabetes and neurodegenerative disorders. This makes GSK-3
an important drug target. The majority of the reported GSK-3
inhibitors are ATP analogues or other small drug-like molecules,
most of them nonselective (6-12). Competitive peptide inhibitors
selectively target a specific signaling pathway of GSK-3 (13). The
design of novel potent selective inhibitors depends on detailed
structural knowledge and a mechanistic understanding of the
substrate-kinase interactions at the substrate binding site
(denoted SBS) of the kinase (14).
GSK-3 recognizes its substrates by the sequence recognition
motif SXXXS(p) (where X stands for any residue and S(p) is
a phosphoserine), and it phosphorylates the first serine in this
sequence, using an ATP molecule which resides at the catalytic
site. The heat shock factor-1 (HSF-1) is a substrate of GSK-3.
It is a sequence-specific transcription factor that regulates mam-
malian heat shock genes atthe transcriptionallevel. Its transcrip-
tional regulatory domain contains the proline-rich sequence
KEEPPSPPQSP located at 298-308. Its activity is repressed by
the primary phosphorylation of Ser
307, carried out by mitogen-
activated protein kinase (MAPK). The product, KEEPPSPPQS-
(p)P, is next phosphorylated at Ser
303 by GSK-3 (15, 16), which
appears to finalize the inhibition cascade.
Derivedfromthepresumeddockingsiteofthephosphorylated
HSF-1 regulatory domain, the substrate-competitive peptide
inhibitor L803 was designed with the mutations Glu3Ala and
Ser6Ala (17). In vivo assays demonstrated its antidepressant-like
activity (18) as well as improvement in glucose homeostasis in
ob/ob mice (19). The inhibitor, KEAPPAPPQS(p)P, is assumed
to interact noncovalently with the key interacting residues of
GSK-3β at the SBS by occupying the catalytic groove and
preventing the docking of the substrate. Specifically, the nega-
tively charged phosphoserine, Ser10p, interacts electrostati-
cally with positively charged residues Arg
96,A r g
180, and Lys
205
(20-22). Additional information on other key interactions
between the inhibitor and GSK-3β is needed to fully under-
stand the mechanism of GSK-3β inhibition as to date there is no
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high-resolution structure of GSK-3β bound to one of its protein
substratesorproteininhibitors.Figure1presentsthestructureof
GSK-3β,highlightingtheactivesiteandimportantregionswhich
govern substrate and inhibitor binding. These include two short
motifs inside the catalytic site of the enzyme which are con-
servedamongallspeciesandkinases:HRD(179-181) andDFG
(200-202). Both motifs are known to play a crucial role in the
catalytic activity of all kinases (23).
An open question related to GSK-3β function is how the
phosphorylated Tyr
216 renders the enzyme active. The autophos-
phorylation event at residue Tyr
216 causes the kinase to become
active, but there is no atomic level description of this activation.
This mystery is compounded by the negligible structural differ-
ence between the crystal structures of the unphosphorylated
(Tyr
216) and autophosphorylated (Tyr
216(p)) enzyme (20, 24).
To date, several theoretical methodologies were developed to
complement experimental observations, to characterize the key
interactionsofkinaseswiththeirsubstratesandinhibitors,andto
predict novel drug candidates. These include feature selection
and linear/nonlinear regression (25), SAR and QSAR studies
(9, 12, 26), bioinformatics methods (21, 27), pharmacophore
characterization (28, 29), and molecular dynamics (MD) simula-
tions (30-32).
In this study we use MD simulations to elucidate the interac-
tions of GSK-3β with its substrates and inhibitors. By structural
andatomisticcomparisonofthesimulatedunboundstructuresof
the dephosphorylated (denoted GSK-3β3ATP) and the phos-
phorylated (denoted GSK-3β(p)3ATP) complexes, we show that
the autophosphorylation event at Tyr
216 is likely to render the
kinase active by controlling accessibility. We further perform
MD simulations of GSK-3β(p)3ATP bound to the HSF-1 regu-
latory domain, and to its analogous inhibitor L803, and iden-
tify the key residues at the SBS involved in the ligand-enzyme
interactions. Finally, we locate a putative allosteric binding site
(denoted ABS) at the N-terminal small lobe that is homologous
to other kinases and characterize its key interactingresidues with
the substrate, the inhibitor, and the phosphorylated substrate.
We show that substrate and especially phosphorylated substrate
binding at the ABS induce distal conformational changes at the
catalytic site, toward an activated state of GSK-3β(p). Our find-
ings of substrate allosteric regulation are supported by several
experimental studies of other serine-threonine kinases; one of
them, CDK2(33), is also a member of the CMGC kinase family.
Since protein kinases are key enzymes during the entire cell
cycle, their activity is highly regulated. Kinases are turned on or
off by phosphorylation (sometimes by the kinase itself), by bind-
ing anactivator protein, aninhibitor protein, or small molecules.
Most kinase activities are regulated via the activation loop
located at the active site. To date, only few studies point to
remote regulation sites. As a consequence, allosteric regulation
mechanisms in kinases are less understood. A hint for allosteric
regulation in GSK-3β comes from the finding that the mutation
Leu128Ala at the N-lobe, in the PIF-pocket, abolished the phos-
phorylation of axin that binds at a distal site in the C-lobe (24),
without affecting the phosphorylation of phosphate-primed
substrates (34). Here, we aim to gain better insight into allosteric
regulation in GSK-3β and how it is linked to the kinase activity.
We believe that enhanced mechanistic understanding of the allo-
steric regulation of GSK-3β will aid rational drug design for this
important enzyme.
METHODS
The system setup procedure included modeling of GSK-3β,
and of the substrate and peptide inhibitor L803 (18, 19)i nt h e
enzyme active site and in the allosteric binding site. These were
followed by simulations of the unbound systems (20 ns), and
ligand-bound kinase (40ns).Each bound complex was simulated
twice using different starting velocities.All modeling and simula-
tions used the CHARMM27 force field (35). Figure 2 sum-
marizes the modeling and simulation flow.
Modeling GSK-3β. The structure of GSK-3β has been
solved in complex with different ligands, often surrounding an
ATP analogue. Since the CR RMSD difference between these
crystal structures is negligible except for the P-loop (residues
64-69), we utilized several of these structures for modeling. The
structure of the unphosphorylated inactive unbound enzyme with
ATP(apoGSK-3β3ATP)wasderivedfromPDBcode1PYX(6),
andtheexistingATPanalogue,ANP,wasreplacedbyATPusing
CHARMM (36). To model the phosphorylated active unbound
enzymewithATP(apoGSK-3β(p)3ATP)(37,38),thephosphate
ion coordinates of Tyr
216 were taken from the bound structure
(PDB code 1O9U) (24) and added to our unphosphorylated
enzyme model. Hydrogens were added using CHARMM (36).
The model of GSK-3β(p)3A T Pw a su s e da sas t a r t i n gp o i n t
for simulations of the unbound and allosteric bound complexes.
The ATP coordinates from the most prevalent conformation of
the unbound system were used as a starting point for all bound
simulations.
Modeling the Substrate and Inhibitor at the SBS. To
date, no crystal structure has been solved for neither the sub-
strate (regulatory domain of HSF-1) nor the inhibitor L803.
FIGURE 1: The structure of unbound GSK-3β3ATP in ribbon dis-
play. The small N-lobe (35-138) and large C-lobe (139-386) are
marked. The three regions important for the catalytic activity are
highlighted in different colors: the P-loop (64-69) in green, the activa-
tion loop (200-226) in purple, and the RC-helix (96-104) in blue.
The ATP appears in CPK colors inside its cavity, governed by
the P-loop gatekeeper. The residues that govern the activation of
GSK-3βappearinbeads.TheseareArg
96,Arg
180,andLys
205which
comprise the basic binding groove, Asp
200 and Asp
181 from the
highly conserved motifs DFG (200-202) and HRD (179-181) at
the catalytic site, and Glu
97, Lys
85, and phosphotyrosine Tyr
216(p)
that are responsible for rendering the enzyme active.10892 Biochemistry, Vol. 49, No. 51, 2010 Buch et al.
We hypothesized that they bind to the SBS. Modeling these into
theactive siteinvolved two steps:(1)creationof an N0-truncated,
nonphosphorylated substrate based on a template from a solved
structure of a similar peptide and (2) docking of this peptide into
the binding site using FlexPepDock (39), including the addition
of the N0 residues and the C0 phosphate ion.
(1) Modeling of an Initial Peptide Conformation in the
Substrate Binding Groove. PDB code 1H8F was chosen as
an initial starting structure since the small ligand HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), from the crys-
tallization buffer, has a sulfonate ion bound to the Ser
10(p) basic
binding pocket of Arg
96,A r g
180,a n dL y s
205 with extensive hydro-
gen bonds. The phosphate ion of Tyr
216 and the P-loop were
modeledasin1O9U,wheretheaxinpeptideisboundatadistalsite
a w a yf r o mt h ea c t i v es i t e .T h es t r u c t u r eo ft h eS l p - 7 6m o t i f( P D B
code 1YWO:P) (40) with the sequence PPVPPQRP was next used
as a template for our substrate KEEPPSPPQS(p)P. The substrate,
truncated at the N0 KEE, was modeled using the backbone of the
polyproline Slp-76 motif and was placed such that the Cβ-Oγ
bond of Ser
10 overlaps the sulfonate bond of the HEPES molecule
of1H8F.The restofthe peptidewaslooselyorientedin thebinding
cavity. Thus, the starting structure contained 1H8F:A and a
truncated substrate placed in its approximate orientation.
(2) Refinement and Complementation of the Peptide
Conformation in the Binding Groove Using FlexPepDock.
The starting structure with the peptide in the binding groove was
optimized using the FlexPepDock program (39), in which the
backboneandrigidbodyorientationofthepeptideareoptimized
iteratively, including on-the-fly side-chain optimization of pep-
tide and enzyme. The simulations were performed with known
constraints, including the positioning of Ser
10 Cβ and Oγ in the
phosphatebindingpocketand adistanceof3(1A ˚ betweenSer
6
Oγ and the catalytic Asp
181 Oδ2( 23). In a first step, 100 models
were created. Almost all 100 generated models converged to
within 1-2A ˚ peptide backbone RMSD of the starting con-
formation (Supporting Information Figure S1), and the model
withthe most extensive hydrogen bonds among the top 5 scoring
models was selected. The truncated peptide was modeled first
without the N0 (KEE) tail based on the peptide backbone
structure that we obtained and high-resolution distance con-
straints with the binding site. On the other hand, we had no
structuralinformationonthe tail. Followingthe model selection,
the N0 tail (KEE) was added in an extended conformation (j/ψ
of (135 ) and docked with softer constraints to produce 1000
additional structures, from which the top-scoring model was
selected. Finally, phosphate was added to the substrate Ser
10 and
enzyme Tyr
216 (as the enzyme backbone conformation is fixed
during thedocking simulations,thisphosphate isnot expected to
affect the overall enzyme conformation), and a short minimiza-
tion was applied. To model the inhibitor, we mutated the
(resulting) substrate structure by E3A and S6A.
Modeling the Substrate and Inhibitor at the ABS. The
allosteric binding site was detected when trying to dock the
inhibitorontothe kinaseusing arigidgeometric protein-protein
docking procedure, without any distance constraints. This pro-
cedure was used to assess the docking solution obtained by
FlexPepDock(39).Surprisingly,previousexperimentalworkson
several kinases from other families have discovered this same
allosteric binding site (41-43). We therefore chose to further
explore this site of GSK-3β.
(1)ModelingtheConformationofthePeptideSubstrate.
We conducted a conformational search on the substrate, p-sub-
strate(product),and inhibitor using the Cerius2 software(http://
www.accelrys.com/products/), after modeling by CHARMM
(36). Since the five prolines that exist in the peptide ligand
introduce strong spatial restraints on the conformation of the
11 amino acid long peptide, we settled for 1000 distinct con-
formations. We obtained three clusters and picked a representa-
tive from each.
(2) Global Search of Peptide Binding Pockets on GSK-
3β. We next applied PatchDock (44)f o l l o w e db yF i r e D o c k( 45)
to dock the inhibitor onto the enzyme. We chose the top three
scoring models for MD simulations. The top scoring solution
exhibited a complete geometric fitting throughout the 40 ns
simulation, with the inhibitor firmly positioned at the binding
site.Intheothertwosolutions,theinhibitorbindingtothekinase
was not stable, and the simulations halted after 3-4 ns. The
dockingofthesubstrateandp-substrateontotheABSwasbased
on the orientation of the inhibitor bound at the ABS.
Simulations and Analysis. All systems were solvated in a
box containing 14625 TIP3P water molecules (46), with a mini-
mum margin of 9 A ˚ between the box facets and the solute atoms.
To simulate physiological conditions that enable kinase activity,
Mg
2þ ions were added at a concentration of 50 mM, near the
ATP, and Cl
- ions were added to neutralize the systems. The
systems were minimized with the steepest-decent algorithm fol-
lowedbytheadoptedbasisNewton-Raphson(ABNR) method,
gradually decreasing the harmonic force restraints to zero. These
setup stages were performed by CHARMM (36). Following
minimization, the systems were gradually heated to 310 K and
equilibrated for 50 ps. The unbound and ligand-bound systems
were run for 20 and 40 ns, respectively, using an NVT ensemble
with periodic boundary conditions and a time step of 1 fs. The
SHAKE algorithm was used to restrain all carbon-hydrogen
bonds. Long-range electrostatic interactions were computed
FIGURE 2: Modeling and simulation flow. GSK-3β(p) denotes the
phosphorylatedkinaseatTyr
216.SeveralX-raystructuresareusedto
model GSK-3β depending onwhetherit is phosphorylatedatTyr
216,
and whether it is bound. These structures together with the con-
formational search, docking procedures, and MD simulation proto-
col are detailed in the Methods section.Article Biochemistry, Vol. 49, No. 51, 2010 10893
using the particle mesh Ewald summation (47). The vdW non-
bonded cutoff was set to 12 A ˚ with a smoothing cutoff of 10 A ˚ .
Snapshots were saved every 5 ps. The MD simulation protocol
including heating, equilibration, and production was carried out
by NAMD (48).
All snapshots of a simulated complex were grouped into five
clusters by the K-means algorithm according to the CR RMSD
differencebetweenthe“activationloop”,the“RC-helix”,andthe
“P-loop”. From the most populated cluster with minimal stan-
dard deviation, we picked a snapshot which represents the most
visited conformation along the simulation. This conformation
was further analyzed and presented in this work. All structural
alignments of the obtained GSK-3β conformations with other
kinases were done using Multiprot (49). All images were pro-
duced by VMD (50).
RESULTS
The Apo GSK-3β. To obtain atomic level insight into GSK-
3β activation, we first modeled the inactive GSK-3β3ATP and
the active GSK-3β(p)3ATP (see Methods). These unbound
structures were simulated for 20 ns. The final structure of the
GSK-3β(p)3ATPsimulationsservedasstartingpointsforfurther
ligand-bound simulations. Figure 3 presents both GSK-3β(p)3
ATPandGSK-3β3ATPfinalstructuresandhighlightsimportant
functional sites. We observed that the substrate binding site
opens for substrate access in the complex GSK-3β(p)3ATP due
to the addition of the phosphate group to Tyr
216 (Figure 3, left
panels) and closes in GSK-3β3ATP where Tyr
216 is not phos-
phorylated (Figure 3, right panels). This structural change is
mainly governed by three surrounding regions: the RC-helix
(residues 96-104), the activation loop (residues 200-226), and
the P-loop (residues 64-69). These regions control the closing
andopeningofthesubstratebindingsiteinGSK-3β(p)3ATPand
GSK-3β3ATP, respectively. In addition, we monitored intra-
molecular electrostatic interactions at the active site throughout
the simulations (summarized in Supporting Information Table
S1). A comparison of the intramolecular interactions in both
unbound complexes reveals that in GSK-3β3ATP Arg
220 inter-
actswithATPγ-phosphateandAsp
181fromtheconservedHRD
motif (residues 179-181), and Arg
96 interacts with Asp
200 from
the conserved DFG motif (residues 200-202), both in the
catalytic site, thus closing the active site. However, in GSK-
3β(p)3ATP, Arg
220 and Arg
223 are neutralized by Tyr
216(p), thus
broadening the catalytic groove and enabling full substrate
access. Structural analyses show that both the kinase and ATP
undergo minor global structural changes (Supporting Informa-
tion Figure S2). The low root-mean-square deviations (RMSD)
ofthekinaseandATPinbothsystemssuggestthattheycanserve
as a starting point for further MD simulations with bound
ligands.
Peptide Binding at the Substrate BindingSite (SBS). We
investigatedthekeyinteractionsbetweentwopeptides:theHSF-1
regulatory domain (“the substrate”) and the inhibitor L803 at
the enzyme’s SBS. Both are 11 amino acids long, and their Ser
10
residueis phosphorylated. We obtained the N0-truncated,unphos-
phorylated substrate by homology modeling, docked it in the
active site, and added the remaining N0 residues and phos-
phate group in situ (see Methods). The inhibitor model was
obtained from the substrate by manual coordinate replacement
of Glu3Ala and Ser6Ala. The following two systems were
constructed and simulated: substrateSBS3GSK-3β(p)3ATP and
inhibitorSBS3GSK-3β(p)3ATP (subscript “SBS” indicates dock-
ing at the SBS). SubstrateSBS (or inhibitorSBS) was docked with
the following binding site putative physicochemical con-
straints (51): (a) close proximity of the ligand Ser
10(p) to the
kinase Arg
96,A r g
180, and Lys
205 at the SBS, and (b) close proxi-
mity between the substrateSBS Ser
6 (to be phosphorylated) and
the kinase conserved catalytic Asp
181. The latter is known to
initiate the catalytic process by attacking the substrate Ser
6,
thereby forming an alcoholate ion that attacks the ATP
γ-phosphategroup (23).Table 1 summarizes the mostsignificant
interactions observed in these systems throughout the simula-
tions. Interestingly, in all systems, both substrateSBS and inhibi-
torSBS maintain electrostatic interactions between Ser
10(p) and
the positively charged residues Arg
96,A r g
180, and Lys
205 (Figure
4a,b). In addition, the hydrogen bonds and hydrophobic inter-
actions of the proline residues at the peptides’ C-terminal end
hold throughout the simulations. However, while the N-terminal
end of the inhibitor remains intact, the N-terminal end of the
substratedepartsfromitsinitiallocation.TheCRRMSDofboth
peptides (Figure 4c) depicts the structural stability of the
inhibitor vs the substrate in the active site.
BothsubstrateSBSandinhibitorSBSbindtocommonresiduesat
the SBS, with the inhibitor L803 occupying the same binding
groove geometrically, sterically blocking access of any potential
substrate. Previously, Ilouz and co-workers modeled the sub-
strate pCREB (21) and the GSK-3β N-terminal pseudosub-
strate (52) bound at the SBS. Comparing the peptide-kinase
interactionsofbothstudiesandtheinteractionsofHSF-1-GSK-
3β(p) orL803-GSK-3β(p)revealsthatArg
96,Ar g
180,andLys
205
are the only common amino acids of GSK-3β(p) that interact
with the peptides at the SBS, forming electrostatic interactions
with the substrate/inhibitor primed phosphate group. Gln
89 and
Asn
95 which interact with pCREB and are believed to play an
important role in substrate and pseudosubstrate recognition do
not interact with the HSF-1 fragment or L803. These adopt a
fibril-like structure as opposed to the bulkiness of pCREB and
GSK-3β N-terminal pseudosubstrate. Therefore, both Gln
89 and
Asn
95 may not affect HSF-1 or L803 recognition directly. On the
other hand, we hypothesize that the conserved Phe
67,b e l i e v e d
to stabilize the native conformation of the kinase catalytic site
for ATP binding, may play the same role upon HSF-1 or L803
binding.
Recently, London et al. (53)s h o w e dt h a tp e p t i d e -protein
interactionsaredominatedbyahighnumberofhydrogenbonds,
mainly contributed by peptide backbone atoms. Thus, we mea-
sured the average number of hydrogen bonds between the pep-
tides and GSK-3β(p) along the simulations (Supporting Infor-
mation Figure S3). The results of both CR RMSD and hydrogen
bonds indicate a slightly tighter binding of the inhibitor to the
kinase. This observation may stem from electrostatic repulsion
betweenthesubstrateconsecutiveGlu
2andGlu
3whichmayshift
its conformation and therefore interfere with the peptide-sub-
strate binding at the active site. The mutation Glu3Ala in the
inhibitoreliminatesthisrepulsion.Additionally,wedidnotsimu-
latethewholeHSF-1protein(sinceithasnocrystalstructure)but
only its small regulatory domain; the whole substrate structure
may have an impact on the interaction with GSK-3β(p). Never-
theless, ourobservation issupported byexperimental results that
showed L803 efficacy as a potential drug (18).
Ligand Binding at the Allosteric Binding Site (ABS).
(1) Interactions at the ABS. In order to examine the existence
of potential binding sites other than the SBS, a different docking10894 Biochemistry, Vol. 49, No. 51, 2010 Buch et al.
procedure was applied to GSK-3β(p)3ATP with no constraints
(see Methods). The top scoring docking solutions included a new
binding site, located at the small lobe, in the vicinity of the
activation loop, near the surface of the RC-helix, referred to as
“ABS”(see Figure 5). Previous QSARand modelingstudies that
examined ATP-noncompetitive inhibitors of GSK-3β based on
thiadiazolidinone (TDZD) suggested two putative binding sites:
one in the vicinity of the activation loop (similar to our new
indicatedbindingsite)andtheotherintheATPbindingpocket(9).
Surprisingly, the location of the new binding site was recently
identified as a conserved pocket in the protein kinase family (54)
and was found to be structurally homologous to the PIF pocket of
several kinases, where an activator is positioned in the enzyme
crystal structures (PDB codes 1FIN, 3HRF, 1OL5, and 1O6L).
Based on our finding of the ABS and given the structural similar-
ities, we simulated three systems: inhibitorABS3GSK-3β(p)3ATP,
FIGURE 3: The unbound structures of GSK-3β(p)3ATP and GSK-3β3ATP after 20 ns of MD simulations. (a) The final simulation snapshot of
GSK-3β(p)3ATP (colored blue) superimposed on the crystal structure of PDB code 1PYX (colored red) from which the simulation originated.
(b) The final simulation snapshot of GSK-3β3ATP (colored blue) superimposed on the crystal structure of PDB code 1PYX (colored red) from
which the simulation originated. (a) and (b) share the same perspective. The orientation of Tyr
216 is highlighted. (c) The main structural
determinants of the catalytic site of the GSK-3β(p)3ATP system shown in surface representation and colored as follows: the P-loop (residues
64-69)isingreen,theactivationloop(residues200-226)isinpurple,andtheRC-helix(residues96-104)isinblue.Thesedeterminantsareinan
“open” conformation, creating a wide groove. (d) The main structural determinants of the catalytic site of the GSK-3β3ATP system shown in
surface representation and colored as in panel c. The determinants are in a “close” conformation in which the catalytic groove is nearly blocked.
(e) Atomic description of the GSK-3β(p)3ATP active site key residues. The phosphotyrosine Tyr
216(p) is electrostatically bound to Arg
220 and
Arg
223. (f) Atomic description of the GSK-3β3ATP active site key residues. The aromatic ring of Tyr
216 is headed outside of the cleft, allowing
Arg
220 to interact with the ATP γ-phosphate group and with the highly conserved Asp
181.Article Biochemistry, Vol. 49, No. 51, 2010 10895
substrateABS3GSK-3β(p)3ATP, and phosphorylated substrateABS3
GSK-3β(p)3ATP(subscript“ABS”denotesdockingattheABS).
Figure 5 shows the substrateABS and phosphorylated substra-
teABS bound to GSK-3β(p) (panels a and b of Figure 5, respec-
tively) in the same perspective. Table 2 summarizes the inter-
actions of each of the simulated ligands at the ABS along the
simulations. There are two main positively charged sites near or
at the surface of RC-helix in GSK-3β(p): Lys
94 and the adjacent
residuesArg
102 andLys
103.InallligandsSer
10(p) bindstoLys
103,
or Arg
102, or both. The peptide ligands are anchored at Lys
94
near the surface of the RC-helix by the negatively charged Glu
2
and Glu
3. The presence of another phosphate group on Ser
6 in a
phosphorylated substrate further strengthens the docking of the
ligand to the ABS. Based on structural homology of 86%
between GSK-3β(p) and CDK2 (both members of the CMGC
kinase family), the activator cyclinA binds to CDK2 at approxi-
mately the same region as GSK3β(p) binds ligands at the ABS
(33) (Figure 5c). The figure visualizes the high overlap ratio
between the interface of GSK-3β(p)-phosphorylated sub-
strateABS and CDK2-cyclinA.
Arg
96, being an essential residue for phosphate-primed sub-
strates binding at the SBS (34), maintains its initial unbound
conformation along the simulations of the inhibitorABS and
phosphorylated substrateABS. During the simulation of sub-
strateABS, it reorients toward the bound substrate after 20 ns
(Supporting Information Figure S4). As arginine may toggle be-
tweenastableandametastablestateduringregulation(55),theflip
may have no effect on subsequent substrate binding at the SBS.
(2) Allosteric Effect of the Peptide Ligands. To study the
cross-talk between the binding of a ligand at the ABS and the
active site, we monitored the root-mean-square fluctuations
(RMSF)ofstructuralmotifsthatformtheSBS.Figure6presents
the RMSF of the kinase’s main structural determinants in the
simulated systems with the unbound system of GSK-3β(p) as
a reference. A significant reduction in fluctuations is seen with
all tested ligand types at the first nine residues of the activation
loop which includes the “magnesium binding loop” (residues
200-205). Ligand binding also affects the RC-helix region where
fluctuations of residues 96 and 97 are reduced and stabilized by
direct binding of both substrateABS and p-substrateABS. These
results are in accord with Jeffrey et al. (33), Yang et al. (41),
Bayliss et al. (42), and Hindie et al. (43), who examined the effect
of an activator at the PIF binding pocketonthe conformation of
three regions of the bound kinase: the RC-helix, the G-rich loop,
and the activation loop. Theauthors foundthat uponbinding all
three regions are stabilized, adopting an active conformation.
To further understand the differences between the complexes,
weanalyzedthemotioncorrelationofthekinaseCRatoms along
the simulations. Supporting Information Figure S5 displays the
cross-correlation maps of the unbound GSK-3β(p) and bound
substrate and p-substrate systems. The motion of the N-lobe
backboneisautocorrelatedovertimeinallsystems,and itscross-
correlation increases in the bound systems. This implies that,
upon binding, the N-lobe residues move in the same direction
topromotecatalysis.Interestingly,bindingofaligandattheABS
amplifies the correlation between regions in the enzyme com-
pared to the unbound kinase. The main effect upon substrate
and p-substrate binding at the ABS is an amplification of
the correlation of motions between the N- and C-lobes. Several
regions, such as the catalytic loop (residues 182-187) and the
DFG motif (residues 200-202), are correlated with the small
lobe as well. However, the hinge between the N- and C-lobes
Table 1: Interactions at the Substrate Binding Site of Bound GSK-3β
ligand
a interactions with GSK-3β(p)
substrate (regulatory
domain of HSF-1)
Lys
1...Ser
66 (HB)
Lys
1...Phe
67 (vdW)
Glu
2...Ser
66 (HB)
Glu
3...Ser
66 (HB)
Ser
6...ATP γ-phosphate (HB)
Gln
9...Val
214,Ile
217 (vdW)
Gln
9...Arg
180,Ser
203 (HB)
Ser
10p...Lys
94,Arg
96,Arg
180,Lys
205 (Elec)
Pro
11...Lys
94 (Elec)
inhibitor (L803) Lys
1...Asp
260 (Elec)
Glu
2...Arg
220 (Elec)
Pro
4...Arg
220,Tyr
221 (HB)
Pro
5...Arg
220 (vdW)
Pro
7...Ser
219 (HB)
Pro
8...Ile
217 (HB)
Gln
9...ATP γ-phosphate (HB)
Ser
10p...Arg
96,Arg
180,Lys
205 (Elec)
aThe substrate and inhibitor are described in the Methods section.
FIGURE 4: Peptide-ligand binding at the substrate binding site
(SBS). The snapshots of two ligands bound at the SBS were taken
from the most populated cluster of conformations. GSK-3β(p)
appears in surface representation, and the ligands appear in sticks.
Thekeyinteractingresiduesoftheligandsarehighlighted.(a)HSF-1
regulatory domain (the substrate) bound at the SBS. The substrate
Ser
6 is the residue due to be phosphorylated by the kinase. (b) The
inhibitor L803 bound at the SBS. Alanine replaces Ser
6 of the
substrate. The different surfaces in panels a and b reflect bound
and unbound regions. (c) The CR RMSD of both substrate and
inhibitor measured along the 40 ns of simulations.10896 Biochemistry, Vol. 49, No. 51, 2010 Buch et al.
(residues 134-138), the G-helix (residues 262-273) and the
extended loop (residues 285-299), both located at the C-lobe,
are anticorrelated with the N-lobe. These correlations are con-
sistent with the catalytic activity of the GSK-3β(p), since the
P-loop (residues 64-69), the catalytic loop, and the DFG motif
are directly involved in substrate bindings. The cross-correlation
map of a substrate bound at the ABS exhibits high similarity to
the cross-correlation map published by Cheng et al. (30), who
analyzed the motions of cAMP-dependent protein kinase (PKA)
in complex witha small peptideinhibitor (PDB code1L3R) (56).
(3) Analysis of the Activation Mechanism Induced by
Binding at the ABS. To understand the relation between
remote binding at the ABS and catalytic activity, we monitored
intramolecular interactions of key functional residues at the
active site along the simulations, when the ABS is occupied.
Kornev and co-workers (27) have discovered an activation
mechanism which is conserved in all kinases. According to their
findings, the phosphorylation of a residue in the activation loop
promotes activation by folding it correctly. Additionally, kinase
activation occurs when the RC-helix moves inward toward the
catalytic site, such that a tight connection is formed between the
two lobes through alignment and stacking of the “hydrophobic
spine” (residues Leu
95,L e u
106,T y r
164, and Phe
185), formation of
a hydrogen bond in the DFG motif between Asp
184 and Gly
186,
and of a salt bridge between Lys
72 and Glu
91 (PKA numbering is
used). We analyzed the orientation of the corresponding amino
acids in GSK-3β(p) in the bound and unbound systems. We
aligned the structure of the bound PKA (PDB code 2CPK) (57),
which is in an active conformation, with bound GSK-3β (PDB
code1H8F) (20),focusingonthehydrophobicspineresidues(see
Figure 7a), the salt bridge, and the hydrogen bond (Figure 7b)
within the active site. The RMSD of the corresponding spinal
FIGURE 5: Ligandbinding atthe allosteric binding site(ABS).Allcomplexes werefirst superimposed, toenableauniform perspective.(a)GSK-
3β(p) in a surface representation, with the substrate (in orange ribbon) bound at the ABS, in the groove between the N-lobe and C-lobe. The
positivelyandnegativelychargedkeyinteractingresiduesappearasblueandredspots,respectively.Theinsetmagnifiestheinteractingresiduesof
theABSandthesubstrateanddisplaysthemainsecondarystructuresattheN-lobe.ThekeyinteractingresiduesLys
94,Arg
102,andLys
103appear
frombothsidesoftheRC-helix.(b) Magnificationoftheinteractionbetweenthephosphorylatedsubstrate(theproduct)andtheABS.Thesame
key interacting residues Lys
94,A r g
102, and Lys
103 bind to two negative centers at the p-substrate: S
6(p) and S
10(p). (c) The phosphorylated
substrate (product), as it appears in panel b, being projected on the structural alignment of CDK2 and GSK-3β(p). CDK2 is in surface
representation (colored gray), and its residues which are located within 4 A ˚ of the activator protein cyclinA (PDB code 1FIN) are highlighted in
pink(33).Thisperspectiveexhibitsthehighoverlapbetweentheinterfaceproduct,GSK-3β(p),andtheinterfacecyclinA,CDK2.Thestructureof
GSK-3β(p) is not shown, for clarity.
Table 2: Ligand-GSK-3β Interactions at the Allosteric Binding Site
ligand key interactions
inhibitor (L803) Pro
4...Arg
96 (vdW)
Pro
5...Arg
96 (HB)
Pro
7...Arg
96,Ile
100 (vdW)
Pro
8...Phe
175,Ile
177 (vdW)
Gln
9...Lys
103 (HB)
Ser
10p...Lys
103 (Elec)
Pro
11...Phe
175,Gln
365 (vdW)
substrate (regulatory
domain of HSF-1)
Glu
3...Lys
94,Arg
96 (Elec)
Pro
4...Phe
93,Lys
205 (vdW)
Ser
6...Arg
96,Gln
99,G l n
206 (HB)
Pro
7...Gln
99,Ile
100 (vdW)
Pro
8...Lys
103 (HB)
Ser
10p...Arg
102,Lys
103 (Elec)
p-substrate (phosphorylated
regulatory domain of HSF-1)
Glu
2...Ala
92 (vdW)
Glu
3...Lys
94 (HB)
Ser
6(p)...Lys
94,Arg
102,Lys
103 (Elec)
Ser
6(p)...Gln
99 (HB)
Pro
7...Gln
99,Lys
103 (HB)
Gln
9...Ile
177,Phe
175 (vdW)
Ser
10p...Lys
102 (Elec)Article Biochemistry, Vol. 49, No. 51, 2010 10897
residues in GSK-3β (Met
101,L e u
112,H i s
179, and Phe
201)w i t h
regard to the bound PKA was very low (0.96 A ˚ ). In addition, a
hydrogenbondinthe DFG motifwas found between Asp
200 and
Gly
202 and a salt bridge between Lys
85 and Glu
97. The con-
gruence of both of these structures combined with the analysis of
Kornev et al. (27) points to the structure of GSK-3β (PDB code
1H8F) being in an active conformation as well. Thus, a given
kinase could be considered as having an active conformation if
these properties hold. Figure 8 depicts the spinal RMSD and
distanceanalysesofoursystemsalongthesimulations.Thespinal
residues in apo GSK-3β(p) are completely misaligned, compared
to all our bound systems (Figure 8a). As anticipated, both dis-
tances Lys
85-Glu
97 (Figure 8b) and Asp
200-Gly
202 (Figure 8c)
favor a salt bridge and hydrogen bond, respectively, when the
substrate was bound at the SBS. The results in systems where
the peptide is bound at the ABS are less clear particularly for the
inhibitorABS. We further analyzed common representatives from
our simulated systems (see Methods) and crystal structures of
otherkinaseswithligandboundatthesameallostericbindingsite
and another allosteric binding site. Table 3 summarizes these
results. The crystal structures of PKB and GSK-3β with a bound
ligand at their SBS exhibit the lowest spine RMSD (<1.0 A ˚ ).
However, the crystal structures of aurora-A, PDK1, and CDK2
with a ligand bound at their ABS have a higher spine RMSD
(1.0-1.5 A ˚ ). All analyzed crystal structures exhibit a salt bridge
in the active site and, except for PDK1, a hydrogen bond within
theDFGmotif.Noteworthy,thecrystalstructuresofGSK-3β(p)
with a bound peptide at another ABS, in the C-lobe, also exhibit
lowvaluesofspineRMSDandtheexistenceofasaltbridgeanda
hydrogen bond. Therefore, the crystal structures with a ligand
bound at their SBSareconsidered as active,whereas thosewith a
ligand bound at their ABS are considered “partially” active. The
analysis of the simulated bound structures of GSK-3β(p) in this
spirit suggests that the phosphorylated substrate bound at the
ABS could induce partial activation, similar to bound CDK2,
whereasasubstrateboundattheABScouldrenderthekinaseless
active. The inhibitor L803 bound at the ABS could lead to an
evenloweractivity,andtheunboundGSK-3β(p)isbelievedtobe
practically inactive.
DISCUSSION
Here we conducted MD simulations on unbound and peptide
ligand-bound GSK-3β, to investigate substrate and inhibitor
binding. We observe that the autophosphorylation of Tyr
216
rendersthekinaseactivebyallowingfullsubstrateaccessibilityto
its active site. The interactions of Tyr
216(p) observed here fully
FIGURE 6: The CR root-mean-square fluctuations (RMSF) of three
catalytically important regions measured in all bound complexes at
the allosteric binding site. The results were compared to the fluctua-
tions at apo GSK-3β(p). (a) The activation loop. (b) The RC-helix.
(c) The P-loop.
FIGURE 7: Structural alignment between bound PKA (in orange)
and GSK-3β(p) (in silver) with highlighted residues of GSK-3β(p)
that contribute to the kinase activation state (27). (a) The spine resi-
dues His
179,P h e
201,M e t
101, and Leu
112. (b) The salt bridge between
Lys
85 and Glu
97 (on top), marked in black, and the hydrogen bond
between Asp
200 and the backbone nitrogen of Gly
202,m a r k e di n
green. For clarity, both structures are displayed without hydrogens.10898 Biochemistry, Vol. 49, No. 51, 2010 Buch et al.
coincide with both experiments of Dajani et al. (20) and ter Haar
et al. (22), who hypothesized that the possible interactions
between Tyr
216(p) with Arg
220 and Arg
223 may stabilize the acti-
vation loop and facilitate substrate accessibility.
In general, explicit solvent model MD simulation is a method
often used to assess the docking solutions of a ligand and a
receptor. A wrong solution often results in the detachment of the
ligand from the putative binding site and random movements on
the surface of the receptor. The smaller the ligand the higher its
flexibility and, therefore, the sooner the detachment occurs, here
oftenwithin4ns.Ontheotherhand,astableassociationdoesnot
prove the validityofthe modeling;itonlysuggests candidates for
experiment to check.
Generally, peptide inhibitors are more selective than small
molecule drugs. Previous works have created a template for the
designofnewsubstrate-competitiveinhibitorsforGSK-3βbased
on the kinase-specific recognition motif SXXXS(p) and on the
chemicalnatureoftheregulatorydomainofthesubstrateHSF-1.
Based on this template, several potential inhibitors were tested
in vitro and in vivo, and L803 exhibited the highest efficacy (13).
In this work we first analyzed the key interacting residues at the
substrate binding site (SBS) with this regulatory domain (the
substrate) and with its derived inhibitor L803. Our results indi-
cated that substrate binding was more flexible along the simula-
tion than the inhibitor binding. Additionally, our structural
analysis validates the high affinity of the inhibitor to the kinase.
Furthermore, although the L803 is an FDA approved drug for a
few years, our work provides atomistic details of its interactions
with GSK-3β for the first time.
To date, two binding sites in GSK-3β were revealed experi-
mentally: the substrate binding site and a binding site at the
C-lobe where the protein axin binds (24). Here we revealed
another binding site (the ABS) at the N-lobe, near the surface of
the RC-helix. Previously, the mutation Leu128Ala in the ABS
was observed to impair the phosphorylation of axin (34). Inter-
estingly,similarobservationsofaremoteallostericbindingsitein
other serine-threonine kinases which belong to different kinase
families were reported: (a) in Akt/PKB kinase from the AGC
family (28% sequence identity and 70% structural homology)
where the phosphorylated hydrophobic motif (HM) at the
N-lobe promotes a disorder-to-order transition of the RC-helix
leading to an active kinase conformation (41); (b) in aurora-A
kinase (30% sequence identity and 78% structural homology)
belonging to the aurora family, where binding of microtubule-
associated protein TPX2 at the same allosteric region causes
locking of the active conformation of the kinase (42); and (c) in
cyclin-dependentkinaseCDK2 (34% sequence identityand 86%
structural homology) from the CMGC family, as GSK-3β,t h a t
becomes partially active after binding of cyclinA at its RC-helix
surface (33).
On the basis of these observations, we examine the possible
effects of a bound ligand at the ABS on the catalytic site and
kinase activity. Our findings indicate that peptide binding at the
ABS allosterically affects the catalytic site, such that the kinase
shifts from its inactive toward its active conformation. These
indications are supported by the observations of kinase activity
reportedbyKornevetal.(27),whichincludethealignmentofthe
spinal residues, a salt bridge, and a hydrogen bond, all in the
catalytic site, and a correlated motion of the N-lobe and C-lobe,
as previously observed in bound PKA by MD simulation (30).
The induced formation of the salt bridge within the active site
couldbethemostprominentsignforactivationsinceitbringsthe
RC-helix closer to both the P-loop and activation loop, ready to
accept an incoming substrate, thereby increasing the correlation
FIGURE 8: Structuralanalysesoffunctionalresiduesintheactivesite
along20nsofsimulations.ThetrajectoriesofapoGSK-3β(p)andthe
bound complexes were compared to the bound GSK-3β(p) crystal
structure (PDB code 1H8F). In this bound structure, the spine
hydrophobic residues are aligned; there is a salt bridge between
Lys
85 and Glu
97 and a hydrogen bond between Asp
200 and Gly
202.
Theseindicateanactivekinaseconformation.(a)All-atomRMSDof
the four hydrophobic spine residues Met
101,L e u
112,H i s
179,a n d
Phe
201. A high RMSD indicates an inactive kinase conformation.
(b)ThedistanceLys
85-Glu
97.Asaltbridgeisformedatadistancein
range (4 A ˚ ,5A ˚ ). Both substrate bound at the SBS and phosphory-
latedsubstrateboundattheABSexhibitasaltbridgethroughoutthe
simulation.(c)ThedistanceAsp
200-Gly
202.Ahydrogenbondcutoff
is typically less than 3.2 A ˚ . This distance is seen when the substrate
was bound at the SBS and at the ABS.Article Biochemistry, Vol. 49, No. 51, 2010 10899
of motion between the N-lobe and C-lobe. Our theoretical
findings presented in Table 3 support the existence of the ABS
as an allosteric regulation site. Together with our analyses of the
axin allosteric binding site(24, 51), we hypothesize that GSK-3β,
as most (if not all) dynamic proteins (58), has few allosteric bind-
ing sites, where weak transient bindings can promote activity.
Furthermore, since the unbound GSK-3β is inactive, we specu-
late that binding of an effector at such an allosteric binding site
is an essential step for the kinase to become fully active. If the
effector is indeed a substrate, the kinase may be subjected to
feedback regulation. Nonetheless, while the simulations suggest
that our investigated peptides bind at the ABS and induce con-
formational changes related to partial activation, we cannot
overlook the possibility that other (peptide) ligands exhibit this
behavior. The characteristics of effective ligands bound at this
site are yet to be determined.
Here we provided key interacting residues at the GSK-3β
binding sites. Atomic level details of these binding sites may
facilitate future discovery of potential drugs. However, addi-
tional work is needed to investigate peptide interactions with
kinases toachieve high specificity and affinity. Allosteric binding
sitesareathemeofgrowinginterest(58-61),andinvestigationof
homologous binding sites in other kinases may lead to increased
repertoire of drug design of both small molecules and peptides.
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